38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis – October 26-28, 2022
The following summarizes some of the highlights from Day 2 of ECTRIMS 2022.
Neurology
ECTRIMS 2022 HIGHLIGHTS – THURSDAY, OCTOBER 27 EDITION
October 27, 202238th Congress of the European Committee for Treatment and Research in Multiple Sclerosis – October 26-28, 2022
The following summarizes some of the highlights from Day 1 of ECTRIMS 2022.
Re-evaluating the benefit-risk of high-efficacy treatment in MS
October 3, 2022Click here to take the survey on HE Benefit-risk
The management of multiple sclerosis has begun to shift away from the traditional escalation model – intensifying therapy in response to ongoing disease activity or progression – to one in which high-efficacy DMTs are used earlier in the clinical course. Read More
Three biomarkers of DMT adverse effects proposed
August 25, 2022A new review has summarized three potential biomarkers of adverse effects that may occur with disease-modifying therapies used in the treatment of MS (Kreft et al. J Neurol 2022;269:5192-5193). (Free references below.) All results are preliminary and further validation is required.
Is a cell-depleting DMT safe prior to HSCT?
August 9, 2022Long-acting disease-modifying therapies do not appear to increase the risk of complications following autologous hematopoietic stem cell transplantation (aHSCT), according to a retrospective study from Sweden (Kvistad et al. J Neurol Neurosurg Psychiatry 2022;93:844-848). Read More